Company Focus
Moderna
Latest Moderna News
Biotechnology
A staggering 800% increase in licensing agreement deal values for messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals was recorded over 2019 to 2024 year-to-date (YTD), driven by the remarkable success of mRNA vaccines during the COVID-19 pandemic. 16 October 2024
Related News
Insights
Company Spotlight
A biopharma company developing products for the treatment of human disease, including immunology, metabolism, cardiology and ophthalmology.
Latest News & Features of interest to Moderna
Biotechnology
Boston, Massachusetts-based biotech Cue Biopharma
has appointed industry veteran Lucinda Warren as chief business officer (CBO). 10 September 2024
Biotechnology
Epsilogen, a specialist in the development of immunoglobulin E (IgE) antibodies to treat cancer, has announced the completion of a £12.5 million ($16.4 million) Series B expansion financing. 9 September 2024
Biotechnology
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
Pharmaceutical
Israeli-headquartered RedHill Biopharma has announced the placement of its low-dose rifabutin-triple therapy, Talicia, as an empirically-prescribed fist-line choice for Helicobacter pylori (H. pylori) infection in new American College of Gastroenterology (ACG) guidelines 9 September 2024
Pharmaceutical
Last week’s research news included French pharma major Sanofi releasing mixed Phase III results for it tolebrutinib in progressive multiple sclerosis. Also of note, US vaccine developer Vaxcyte announced strong early-stage trial results for its VAX-31 in pneumococcal disease. On the regulatory front, US drugmaker Travere Therapeutics gained full approval from the US Food and Drug Administration (FDA) for its kidney disease drug Filspari. US cancer drug developer IN8bio announced a prioritization of its R&D pipeline to focus on INB-100 in acute myeloid leukemia, along with a workforce cutback. 8 September 2024
Pharmaceutical
The European Medicines Agency’s (EMA) safety committee (PRAC) has recommended measures to minimize serious outcomes of agranulocytosis, a known side effect caused by the painkiller metamizole. 7 September 2024
Biotechnology
US RNA medicines developer Stoke Therapeutics has announced the appointment of Eric Olson as chief business officer. 7 September 2024
Biotechnology
The Institute for Clinical and Economic Review (ICER) has posted its revised Evidence Report assessing the comparative clinical effectiveness of three medicines for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). 6 September 2024
Pharmaceutical
San Diego, USA-based Travere Therapeutics saw its shares close up more than 8% at $10.75 yesterday on positive news form the US regulator. 6 September 2024
Pharmaceutical
In an interview with Danish national public radio broadcast station DR, Henrik Juuel, chief financial officer of vaccine maker Bavarian Nordic, reacted to public calls for the company to lower the price of its mpox vaccine. 6 September 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
22 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze